Atul Varadhachary

Atul Varadhachary is a distinguished leader in the life sciences sector, currently serving as the Chief Executive Officer of Radiomer Therapeutics since January 2024, focusing on innovative targeted radiopharmaceuticals. Varadhachary has been the Managing Partner at Fannin since June 2013, overseeing numerous biotech and medtech programs. Additionally, Varadhachary has held the role of Chief Executive Officer at Allterum Therapeutics since July 2018, where the company is developing a first-in-class cancer treatment. Varadhachary is actively involved in several organizations, including serving on the Advisory Committee on Childhood Cancers for the Cancer Prevention and Research Institute of Texas and contributing as a board member for both BioHouston and Pulmotect, Inc. Prominent involvement in entrepreneurship is highlighted through leadership roles in TiE and an adjunct professorship at Rice University, where Varadhachary has educated future leaders in entrepreneurship and biotechnology. Varadhachary holds a Ph.D. in Physiology from The Johns Hopkins University School of Medicine and an M.D. from the University of Mumbai.